Cancer Immunology
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributio...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04152naaaa2201249uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_77108 | ||
| 005 | 20220111 | ||
| 020 | |a books978-3-0365-2572-3 | ||
| 020 | |a 9783036525730 | ||
| 020 | |a 9783036525723 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2572-3 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Subramanian, Subree |4 edt | |
| 700 | 1 | |a Zhao, Xianda |4 edt | |
| 700 | 1 | |a Subramanian, Subree |4 oth | |
| 700 | 1 | |a Zhao, Xianda |4 oth | |
| 245 | 1 | 0 | |a Cancer Immunology |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (316 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a NKG2D | ||
| 653 | |a CAR T | ||
| 653 | |a IL-7 | ||
| 653 | |a prostate cancer | ||
| 653 | |a cell therapy | ||
| 653 | |a CD19-CAR-T | ||
| 653 | |a B cell aplasia | ||
| 653 | |a KIR | ||
| 653 | |a PD-1 | ||
| 653 | |a inhibitory CAR | ||
| 653 | |a tumor-infiltrating lymphocytes | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a immunotherapy | ||
| 653 | |a NK cells | ||
| 653 | |a cancer stem cells (CSCs) | ||
| 653 | |a antibody-dependent cellular cytotoxicity (ADCC) | ||
| 653 | |a differentiation | ||
| 653 | |a cytotoxicity | ||
| 653 | |a IFN-γ | ||
| 653 | |a osteoclasts | ||
| 653 | |a MICA/B mAb | ||
| 653 | |a DNA methylation | ||
| 653 | |a RNA methylation | ||
| 653 | |a S-adenosylmethionine (SAM) | ||
| 653 | |a cancer | ||
| 653 | |a innate immunity | ||
| 653 | |a adaptive immunity | ||
| 653 | |a T cells | ||
| 653 | |a m6A | ||
| 653 | |a PD-L1 | ||
| 653 | |a resistance | ||
| 653 | |a immune checkpoints | ||
| 653 | |a cancer vaccine | ||
| 653 | |a combination immunotherapy | ||
| 653 | |a TCR diversity | ||
| 653 | |a organ transplantation | ||
| 653 | |a carcinoma | ||
| 653 | |a epidemiologic studies | ||
| 653 | |a immunosuppression | ||
| 653 | |a CTLA-4 | ||
| 653 | |a Treg cells | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a CD28 | ||
| 653 | |a antigen-presenting cells | ||
| 653 | |a IL15 | ||
| 653 | |a colon cancer | ||
| 653 | |a melanoma | ||
| 653 | |a uveal | ||
| 653 | |a BAP1 | ||
| 653 | |a anti-PD-1 | ||
| 653 | |a anti-CTLA-4 | ||
| 653 | |a TIL | ||
| 653 | |a classical and endemic Kaposi Sarcoma | ||
| 653 | |a systemic treatment | ||
| 653 | |a multi-state modelling | ||
| 653 | |a treatment free interval | ||
| 653 | |a chemotherapy | ||
| 653 | |a interferon | ||
| 653 | |a triple negative breast cancer | ||
| 653 | |a immunomodulation | ||
| 653 | |a bispecific antibody | ||
| 653 | |a sortase A | ||
| 653 | |a chemo-enzymatic approach | ||
| 653 | |a anti-CD20 antibody | ||
| 653 | |a Fab | ||
| 653 | |a BiFab | ||
| 653 | |a colorectal cancer | ||
| 653 | |a dendritic cells | ||
| 653 | |a Atypical Chemokine Receptor 4 (ACKR4) | ||
| 653 | |a T-cell priming | ||
| 653 | |a immune checkpoint blockade | ||
| 653 | |a primary liver cancer | ||
| 653 | |a kynurenine pathway | ||
| 653 | |a immune evasion | ||
| 653 | |a indoleamine 2,3 dioxygenase 1 | ||
| 653 | |a tryptophan 2,3 dioxygenase 2 | ||
| 653 | |a IDO inhibitor | ||
| 653 | |a antigen presenting cells | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4727 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/77108 |7 0 |z DOAB: description of the publication |